GT Biopharma Inc. (GTBP)
NASDAQ
Closed
Sep 18, 2026
Day's Range
7.1152 wk Range
0.2220Profile - GTBP - GT Biopharma Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
1
GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.
Profile Details
Type
Common Stock
Address
315 Montgomery Street
City
San Francisco
State
CA
Zip
94104
Country
United States
Phone
415 919 4040
Key Executives - GTBP - GT Biopharma Inc.
Key executives
Cross Listings - GTBP - GT Biopharma Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
